However, it is unclear whether such tests can detect all tumor subtypes. We investigated whether the CellSearch test could recognize all subtypes of breast cancer, including normal-like, basal, HER2-positive, and luminal A and B tumor cells.
The CellSearch circulating tumor cell test is the only diagnostic test that is currently approved by the US Food and Drug Administration as an automated test to detect and enumerate circulating tumor cells ( 4 ) . Briefl y, a blood sample that contains many leukocytes and few circulating tumor cells is drawn into 10-mL CellSave Preservative Tubes (Veridex LCC), which contain EDTA as an anticoagulant and a cellular preservative. The blood is maintained at room temperature and subsequently processed within 72 hours of collection by use of the CellSearch system (Veridex LLC), which consists of the CellTracks Autoprep (an automated sample preparation system), the CellSearch epithelial cell kit (to enrich for cells expressing EpCAM and to label nuclei, leukocytes, and epithelial cells), and the CellSpotter Analyzer (a semiautomated fl uorescencebased microscopy system that permits computer-generated reconstruction of cellular images). By use of the CellSearch epithelial cell kit, circulating tumor cells are isolated with anti-EpCAM antibodies coupled to microscopic iron particles, and complexes of circulating tumor cells bound to anti-EpCAM -coupled iron particles are "pulled" out of the blood sample by use of powerful magnets. Unbound cells and the remaining plasma are aspirated, and the immunomagnetically isolated cells are permeabilized and stained with 4 ′ ,6-diamidino-2-phenylindole (to detect nuclei); anti-CD45 antibodies labeled with allophycocyan (to detect leukocytes); and anticytokeratin 8, 18, and 19 antibodies labeled with phycoerythrin (to detect epithelial cells). After incubation with staining reagents, the magnetic separation is repeated and excess staining reagents are removed by aspiration. In the fi nal processing step, the immunomagnetically isolated cells are resuspended in a MagNest Cell Presentation Device (Veridex LLC). This device consists of a chamber and two magnets that orient the immunomagnetically labeled cells for analysis by use of the CellSpotter Analyzer, a four-color semiautomated fl uorescence microscope. Finally, circulating tumor cells that are defi ned as nucleated cells with a round to oval morphology that are positive for anticytokeratin antibody binding and negative for anti-CD45 antibody binding ( 5 ) are identifi ed by an operator.
Results of the CellSearch test have been used to monitor disease progression and therapy effi cacy in metastatic prostate ( 6 ) , colorectal ( 7 ) , and breast ( 8 ) cancer. For patients with advanced breast cancer, the number of circulating tumor cells as determined by the CellSearch test has been shown to have prognostic value ( 8 -14 ) . In addition, a change from the baseline number of circulating tumor cells after the fi rst cycle of therapy appears to distinguish
CONTEXT AND CAVEATS

Prior knowledge
Identification of specific subtypes of circulating tumor cells in the peripheral blood of cancer patients can provide important prognostic information, but to be effective, the method used must recognize all tumor cell types.
Study design
The subtype of 19 well-characterized breast cancer cell lines was obtained by use of gene expression profiling, including normallike, basal-like, HER2-positive, and luminal A and B. Cells from each line were mixed with blood from a healthy donor and subjected to the CellSearch circulating tumor cell assay.
Contribution
The CellSearch assay, which uses epithelial cell adhesion molecules on the cell surface, did not recognize normal-like breast cancer cells, although other subtypes were recognized.
Implications
Normal-like breast cancer cells have especially aggressive features, and so assays that recognize this subtype would provide valuable prognostic information. New assays are needed that include antibodies that specifically recognize this breast cancer subtype but not other cell types, including those of hematopoietic origin.
Limitations
Only homogeneous breast cancer cell lines with known subtypes were investigated.
From the Editors
patients who have responded to systemic therapy (who have a decreased number of circulating tumor cells) from those who have not (who have an increased number of circulating tumor cells) ( 15 ) .
Five subtypes of human breast cancers have been identifi ed by global gene expression profi ling, including normal-like, basal, HER2-positive, and luminal A and B ( 16 ) . The normal-like and basal subtypes, which represented 7.8% and 25% of all breast cancers, respectively, in a cohort of 344 breast tumor samples from patients with lymph node -negative disease ( 17 ) , are in general negative for estrogen receptor ( ESR1 ), progesterone receptor, and HER2-neu, and so lack the molecular targets for endocrine therapy and anti-HER2 -directed therapy and therefore have worse treatment options than other subtypes. Because each breast cancer subtype has distinct prognostic and therapeutic characteristics ( 16 , 18 ) , it is important to establish whether each breast cancer subtype expresses the cell surface antigens that are used in assays to isolate and detect circulating tumor cells. It is also important to identify which breast cancer subtypes do not express an antigen and to determine which antibodies could be used instead of or in addition to antibodies that are included in the test for circulating tumor cells.
To investigate whether the CellSearch test recognized all fi ve breast cancer subtypes that are characterized by their intrinsic gene expression profi les as previously described ( 16 , 18 ) , we fi rst determined the subtypes of our well-defi ned panel of 34 human breast cancer cell lines ( 19 ) by global gene expression profi ling, as described previously ( 17 ) . A previous analysis of nearly 150 polymorphic microsatellite markers in this panel of 34 cell lines has shown that each of these 34 cell lines is unique and monoclonal ( 20 ) . As determined by the expression of genes in the intrinsic gene set ( 16 , 17 ) , the complete panel contained 15 luminal cell lines (ie, no clear-cut discrimination between luminal A and B), nine normal-like lines, fi ve basal-like lines, and fi ve HER2-positive cell lines ( Table 1 ) . To validate the gene expression profi ling data, transcript levels of 14 candidate genes were remeasured with Affymetrix GeneChip Exon 1.0 ST Arrays (Affymetrix UK Ltd., Wickham la Wooburn Grn, UK) and real-time reverse transcriptase -polymerase chain reaction. The 14 candidate genes that may as such enable dis crimination between the breast cancer subgroups included genes that are more specifi c for cells of hematopoietic origin ( CD44 and CD45 ); epithelial cell -specifi c genes such as those encoding cytokeratins, EpCAM, and mucin 1; genes encoding markers specifi c for the breast cancer subgroups ( ESR1 , ERBB1 , ERBB2 , CAV1 , and CD24 ); and genes for two well-known epithelialmesenchymal transition markers ( TWIST1 and VIM ). Transcript levels of these 14 genes in all the 34 cell lines were compared with those measured in whole-blood cells from 23 different blood donors before (n = 6 samples) and after (n = 23 samples) being subjected to EpCAM-based CellSearch enrichment to establish which genes were not expressed by blood cells and could be used to specifi cally identify the epithelial tumor cells ( Table 1 ). The study was approved by the Erasmus MC Institutional Review Board. Blood samples were collected from healthy volunteers after written informed consent was obtained. Supplementary Table 1 (available online) lists the gene expression assays used.
We next randomly selected 19 of the 34 cell lines; incubated each cell line with fl uorochrome-conjugated antibodies against CD45, CD24, CD44, or EpCAM, which were chosen to enable a distinction between CD45-positive cells of hematopoietic origin, CD45-negative and EpCAM-positive breast cancer cells, and CD45-negative, CD24-negative, and CD44-positive breast cancer stem cells ( 21 ) ; and used fl ow cytometry to measure the expression of each marker by each cell line ( Table 2 ) . Next, an aliquot (50 -150 cells per aliquot) of each of these 19 cell lines was added to a separate 7.5-mL sample of peripheral blood from a single healthy volunteer donor, and the mixtures were subjected to the EpCAMbased CellSearch assay to isolate circulating tumor cells. Gene expression data of the isolated cells showed that cells with a luminal or HER2-positive subtype were generally isolated by the assay, whereas cells with a normal-like subtype, which lack EpCAM expression, were not isolated or were only partially isolated (eg, MDA-MB-231 cells, which have marginal EpCAM expression) ( Figure 1 ; Supplementary Table 2 , available online). We found that the cell lines with the normal-like subtype . Real-Time PCR system (Stratagene, Amsterdam, the Netherlands). Expression of HMBS , HPRT1 , and GUSB was used as a reference to control sample loading and RNA quality, as described previously (26) . To enable comparison between the different methods of measuring gene expression (Affymetrix GeneChip Exon 1.0 ST arrays and real-time RT-PCR), data were normalized by expression levels that were measured by both methods in a set of seven control cell lines (ie, MDA-MB-435s, MDA-MB-231, CAMA-1, MCF-7, T47D, SK-BR-3, and EVSA-T). EGF = epidermal growth factor receptor; EMA = epithelial membrane antigen; EpCAM = epithelial cell adhesion molecule; EMT = epithelial -mesenchymal transition; CI = confidence interval; RT-PCR = reverse transcriptase -polymerase chain reaction; cDNA = complementary DNA. † One-way analysis of variance was used to test for differences between the four subgroups present in the cell lines, with P < .05 being considered statistically significant. All statistical tests were two-sided.
expressed high mRNA levels of the epithelial -mesenchymal transition markers, TWIST1 ( TWIST1 ) and vimentin ( VIM ) (one-way analysis of variance, two-sided P = .03 and P < .001, respectively) ( Table 1 ) ; however, MDA-MB-231 cells expressed vimentin but did not appear to express TWIST1 ( Supplementary Table 3 , available online). Cells with a normal-like breast cancer subtype express high levels of genes that are characteristic of basal epithelial and adipose cells and low levels of genes that are characteristic of luminal epithelial cells ( 16 ) . The normal-like breast cancer subtype is the only subtype that displays the putative tumor-initiating stem cell phenotype, which includes low expression of CD24 and high expression of CD44 ( 21 , 22 ) ( Table 2 ) and has high expression of both vimentin and TWIST1 ( Table 1 ) . Expression of vimentin and TWIST1 has been used to identify cells that have undergone the epithelial -mesenchymal transition, a process that has been linked to the generation of cells with properties of stem cells and to the ability of breast cancer cells Table 2 , available online). § One-way analysis of variance was used to test for differences between the four subgroups present in the cell lines, with P < .05 from a post hoc Dunett t test being considered statistically significant. All statistical tests were two-sided.
to enter the circulation and seed metastases ( 23 -25 anti-CD44 conjugated with R-phycoerythrin coupled to the cyanine dye Cy7 (PE-Cy7, clone HIB19; eBioscience). We used 7AAD (Sigma-Aldrich, St Louis, MO) to assess viability. Only viable (7AAD negative) cells were analyzed for antigen expression ( red histograms ). Unstained cells ( black histograms ) were used as a negative control. Data are from one representative experiment that was performed three times. Results were similar for all three experiments. EpCAM = epithelial cell adhesion molecule; FITC = fl uorescein isothiocyanate; 7AAD = 7-aminoactinomycin D.
expression of caveolin 1 (Spearman r s = Ϫ 0.26, P < .001). Consequently, antibodies against antigens such as caveolin 1 might be able to specifi cally detect circulating tumor cells from normal-like breast tumors.
A limitation of this study is our use of homogeneous breast cancer cell lines of known subtypes instead of blood samples from patients with breast cancer that had been subtyped. Detection of normal-like breast cancer cells in clinical (breast) cancer samples, which consist of heterogeneous cell populations, will require an assay that uses a mixture of antibodies against different cell surface antigens that are present on circulating tumor cells but absent on cells of hematopoietic origin. Such an assay should be thoroughly validated before clinical use, not only in cultured cell lines but also in clinical samples of known intrinsic breast cancer subtype, as described previously for assays relying only on antiEpCAM antibodies ( 5 ).
In conclusion, an EpCAM-dependent assay could not detect normal-like breast tumor cells. In the future, the identifi cation of antibodies that specifi cally detect normal-like breast cancer cells (which in general have aggressive features) and their inclusion in the CellSearch assay may improve the sensitivity and feasibility of that assay without a loss of specifi city.
